Holistic IP strategy is needed for ‘off-the-shelf’ CAR T cell therapies

With so much investor interest surrounding the potential of allogeneic CAR T cell therapies, the stakes are high for innovators to ensure that their inventions are robustly protected from the start. Justin Wilson, partner and cell & gene therapy sector specialist at Withers & Rogers discusses.

Allogeneic CAR T therapies are generating huge excitement due to their potential use as a cost-effective, readily available treatment for cancer. Unlike autologous CAR T therapies, which involve the extraction and modification of the patient’s own T cells, allogeneic therapies can…